Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran

Thrombosis Journal

Volumn 13, Issue 1, 2015, Pages

  Otsui, Kazunori ^a   Gorog, Diana A ^b   Yamamoto, Junichiro ^c   Yoshioka, Takayuki ^a   Iwata, Sachiyo ^a   Suzuki, Atsushi ^a   Ozawa, Toru ^a   Takei, Asumi ^a   Inoue, Nobutaka ^a  

^a KOBE ROSAI HOSPITAL   (Japan)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Novel oral anticoagulants; Warfarin

Indexed keywords

DABIGATRAN; WARFARIN;

ACTIVATED PARTIAL THROMBIN TIME; AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; EUGLOBULIN LYSIS TEST; FEMALE; GLOBAL THROMBOSIS TEST; HUMAN; JAPANESE (PEOPLE); MALE; NONVALVULAR ATRIAL FIBRILLATION; OCCLUSION TIME; PLATELET REACTIVITY; THROMBIN TIME;

EID: 84949216469     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/s12959-015-0069-6     Document Type: Article

References (12)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-5.
2. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014;38:150-9.
3. Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol. 2010;55:2107-15.
4. Yamamoto J, Inoue N, Otsui K, Ishii H, Gorog DA. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential. Thromb Res. 2014;133:919-26.
5. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-47.
6. Maddry JK, Amir MK, Sessions D, Heard K. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med. 2013;31:462.e1-2.
7. Helldén A, Odar-Cederlöf I, Nilsson G, Sjöviker S, Söderström A, Euler M, et al. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open. 2013;11:13.
8. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30:1885-9.
9. Suzuki S, Otsuka T, Sagara K, Matsuno S, Funada R, Uejima T, et al. Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time. Circ J. 2012;76:755-7.
10. Lazzari MA, Sanchez-Luceros A, Woods AI, Alberto MF, Meschengieser SS. Von Willebrand factor (VWF) as a risk factor for bleeding and thrombosis. Hematology. 2012;Suppl 1:S150-2.
11. Yamamoto J, Yamashita T, Ikarugi H, Taka T, Hashimoto M, Ishii H, et al. Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis. Blood Coagul Fibrinolysis. 2003;14(1):31-9.
12. Nishida H, Murata M, Miyaki K, Omae K, Watanabe K, Ikeda Y. Gorog Thrombosis Test: analysis of factors influencing occlusive thrombus formation. Blood Coagul Fibrinolysis. 2006;17(3):203-7.